Want to see IN:SYNCOMF full AI Analyst Report?
SYNCOMF Stock Chart & Stats
₹13.98
-₹0.26(-1.33%)
At close: 4:00 PM EST
₹13.98
-₹0.26(-1.33%)
Day’s Range― - ―
52-Week Range₹10.21 - ₹19.40
Previous CloseN/A
Volume2.15M
Average Volume (3M)249.72K
Market Cap
₹13.33B
Enterprise Value₹13.32B
Total Cash (Recent Filing)₹1.13B
Total Debt (Recent Filing)₹14.74M
Price to Earnings (P/E)16.2
Beta1.63
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.34
Price to Sales (P/S)1.99
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityA materially higher net margin (~15.6%) and consistent operating margins in the mid-teens indicate stronger earnings power versus recent years. This improved profitability supports sustainable internal funding for R&D, capex, or deleveraging and reduces reliance on external financing over the medium term.
Very Low LeverageThe sharp reduction in debt and extremely low debt-to-equity provide durable financial flexibility, lower fixed financing costs and stronger solvency. This balance-sheet strength improves resilience to industry cycles and enables strategic investment or M&A without pressuring liquidity.
Rebounded Cash GenerationSubstantial operating and free cash flow in FY2026 with FCF covering most of net income demonstrates renewed cash conversion ability. Reliable cash generation enhances capacity for reinvestment, debt reduction and shareholder actions, boosting long-term financial stability if sustained.
Bears Say
Revenue DeclineA year-over-year revenue decline undermines scale and raises questions about demand, pricing or market share dynamics. Sustained top-line contraction would pressure future margin expansion and limit the company's ability to fund growth initiatives from internal cash over the medium term.
Gross Margin CompressionA significant fall in gross margin suggests worsening product mix, pricing pressure, or higher input costs. Margin compression erodes the cushion for operating leverage and makes recent net margin improvements more vulnerable to cost shocks unless the company secures structural cost or pricing fixes.
Uneven Cash-Flow QualityHistoric swings in operating and free cash flow indicate inconsistent cash conversion and operational volatility. Even with FY2026 improvement, this unpredictability could limit reliable reinvestment, dividends or debt servicing and raises execution risk for sustaining improvements.
Syncom Formulation (India) Ltd. News
SYNCOMF FAQ
What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹10.21 and its highest was ₹19.40 in the past 12 months.
What is Syncom Formulation (India) Ltd.’s market cap?
Syncom Formulation (India) Ltd.’s market cap is ₹13.33B.
When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
Syncom Formulation (India) Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 27 days.
How were Syncom Formulation (India) Ltd.’s earnings last quarter?
Syncom Formulation (India) Ltd. released its earnings results on May 22, 2026. The company reported ₹0.27 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.27.
Is Syncom Formulation (India) Ltd. overvalued?
According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued.
Does Syncom Formulation (India) Ltd. pay dividends?
Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
What is Syncom Formulation (India) Ltd.’s EPS estimate?
Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncom Formulation (India) Ltd. have?
Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
Syncom Formulation (India) Ltd. reported an EPS of ₹0.27 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.42%.
Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
Currently, no hedge funds are holding shares in IN:SYNCOMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syncom Formulation (India) Ltd.
Established in 1985 and based in Indore, India, Syncom Formulations (India) Limited specializes in the development, marketing, and sale of a wide array of finished pharmaceutical products. The company provides an extensive portfolio addressing numerous therapeutic categories, including but not limited to pain relief, infectious diseases, cardiovascular health, mental well-being, respiratory ailments, and nutritional deficiencies, alongside specific treatments for conditions like gout and erectile dysfunction, encompassing both generic and specialized medicines. These medicinal preparations are available in various formats such as tablets, capsules, oral liquids, injectables (both liquid and dry vial), dry syrups, topical ointments, inhalers, and herbal formulations. In addition to its core pharmaceutical business, Syncom Formulations also engages in commodity trading and property leasing. The company serves the domestic Indian market and actively exports its products globally.
Technical Analysis
Bajaj Healthcare Ltd
―
Indoco Remedies Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Wanbury Limited
―